Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
467 results about "Nervous system disease" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A disease that affects the brain, spinal cord, autonomic and peripheral nerves.
Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease
InactiveUS20050021103A1Shorten the timeReduce the numberHead electrodesImplantable neurostimulatorsNervous systemIntracranial stimulation
A neurological control system for modulating activity of any component or structure comprising the entirety or portion of the nervous system, or any structure interfaced thereto, generally referred to herein as a “nervous system component.” The neurological control system generates neural modulation signals delivered to a nervous system component through one or more intracranial (IC) stimulating electrodes in accordance with treatment parameters. Such treatment parameters may be derived from a neural response to previously delivered neural modulation signals sensed by one or more sensors, each configured to sense a particular characteristic indicative of a neurological or psychiatric condition.
Owner:CYBERONICS INC
Probe set and kit for detecting whole exons of extended genetic diseases and application of probe set
InactiveCN110499364AComprehensive diagnostic extended whole exome testingIncrease positive rateMicrobiological testing/measurementLibrary creationFresh TissueExon
The invention discloses a probe set for detecting whole exons of extended genetic diseases. The probe set for detecting the whole exons of the extended genetic diseases comprises a standard whole exonprobe set, a whole genome copy number variation probe, and a mitochondrial loop full-length probe, and the genetic diseases comprise 6161 genetic diseases; the standard whole exon probe set can detect the genetic diseases caused by whole exon mutation, the genetic diseases comprise nervous system diseases, metabolic system diseases, endocrine system diseases, digestive system diseases, skeletal system diseases, urinary system diseases, immune system diseases, cardiovascular system diseases, blood system diseases, integument system diseases, ophthalmic system diseases, ear system diseases, respiratory system diseases, and genital system diseases; and the density of the mitochondrial probe is 6X; test samples comprise blood, fresh tissue, FFPE samples, and saliva. The invention discloses using method and kit and application of the probe set for detecting the whole exons of the extended genetic diseases.
Owner:北京凯昂医学诊断技术有限公司
Clustering of recorded patient neurological activity to determine length of a neurological event
Apparatus and method detect a detection cluster that is associated with a neurological event, such as a seizure, of a nervous system disorder and update therapy parameters that are associated with a treatment therapy. The occurrence of the detection cluster is detected when the maximal ratio exceeds an intensity threshold. If the maximal ratio drops below the intensity threshold for a time interval that is less than a time threshold and subsequently rises above the intensity threshold, the subsequent time duration is considered as being associated with the detection cluster rather than being associated with a different detection cluster. Consequently, treatment of the nervous system disorder during the corresponding time period is in accordance with one detection cluster. Treatment therapy may be provided by providing electrical stimulation, drug infusion or a combination. Therapy parameters may be updated for each mth successive group of applications of the treatment therapy or for each nth detection cluster.
Owner:MEDTRONIC INC
System and methods to overcome gravity-induced dysfunction in extremity paresis
The present invention relates to a system for use in rehabilitation and / or physical therapy for the treatment of injury or disease. The system can overcome gravity-induced dysfunction in extremity paresis following stroke or other neurological disorders.
Owner:NORTHWESTERN UNIV +2
System and method for using cardiac events to trigger therapy for treating nervous system disorders
A method of treating a neurological disorder in a patient. In some embodiments, the method includes obtaining a neurological event detection signal, obtaining a cardiac event detection signal, analyzing the timing relationships between the detected neurological and cardiac events to identify matched events, using the matched events to determine whether the cardiac event detection signal facilitates detection of neurological events, delivering a therapy to the patient in response to a cardiac event if the cardiac event detection signal is determined to facilitate detection of neurological events, and changing the therapy delivered based on sensed brain signals from the patient.
Owner:MEDTRONIC INC
Antibodies against Nogo receptor
ActiveUS20050215770A1Promote neuronalPromote axonal regenerationAnimal cellsImmunoglobulins against cell receptors/antigens/surface-determinantsNervous system diseaseNogo Receptors
The present invention relates to antibodies and related molecules that specifically bind to the Nogo receptor (NogoR). Such antibodies have uses, for example, in the treatment of spinal cord injury, brain trauma, paralysis, degenerative nervous system diseases, and stroke. The invention also relates to nucleic acid molecules encoding anti-NogoR antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same.
Owner:HUMAN GENOME SCI INC
Pyrazine derivatives, process for manufacture and use thereof
ActiveUS20120115874A1Good effectImprove abilitiesBiocideSenses disorderPyrazineNervous system disease
The present invention provides pyrazine derivatives of formula Iand pharmaceutically acceptable salts thereof, wherein the designation of R1, R2, R3 and R4 is provided herein. The invention also provides syntheses for preparation of such compounds. The invention further provides methods of use of these compounds and pharmaceutical compositions containing them for treatment and / or prevention of diseases and for manufacture of medicaments. These compounds and pharmaceutical compositions have antioxidative and thrombolytic effects, and thus can be used for the treatment and / or prevention of cerebral stroke caused by ischemia, and used for manufacture of medicaments for the treatment and / or prevention of nervous system diseases caused by excessive amount of radicals and / or thrombosis, infectious diseases, metabolic system diseases, cardiovascular and cerebrovascular diseases, and age-related degenerative diseases.
Owner:JINAN UNIVERSITY
Compositions containing a combination of a creatine compound and a second agent
The present invention relates to the use of creatine compound and neuroprotective combinations including creatine, creatine phosphate or analogs of creatine, such as cyclocreatine, for treating diseases of the nervous system. Creatine compounds in combination with neuroprotective agents can be used as therapeutically effective compositions against a variety of diseases of the nervous system such as diabetic and toxic neuropathies, peripheral nervous system diseases, Alzheimer disease, Parkinson's disease, stroke, Huntington's disease, amyotropic lateral sclerosis, motor neuron disease, traumatic nerve injury, multiple sclerosis, dysmyelination and demyelination disorders, and mitochondrial diseases. The creatine compounds which can be used in the present method include (1) creatine, creatine phosphate and analogs of these compounds which can act as substrates or substrate analogs for creatine kinase; (2) bisubstrate inhibitors of creatine kinase comprising covalently linked structural analogs of adenosine triphosphate (ATP) and creatine; (3) creatine analogs which can act as reversible or irreversible inhibitors of creatine kinase; and (4) N-phosphorocreatine analogs bearing non-transferable moieties which mimic the N-phosphoryl group.
Owner:THE GENERAL HOSPITAL CORP
Transdermal patch containing rasagiline for treatment or prophylaxis of nervous system disease and its preparation process
InactiveUS20090136549A1Improve skin penetrationTreatment or prophylaxis of nervous system diseasesBiocideOrganic active ingredientsTransdermal patchPharmacy
The present invention relates to a rasagiline transdermal patch for treatment or prophylaxis of nervous system diseases, in which the patch comprises an inert backing layer chemically inert to substrate ingredients, a substrate layer comprising rasagiline or a pharmaceutically acceptable salt thereof, and a protective layer to be peeled off before use. The substrate layer is an adhesive system comprising an organic polymer material as basis and an inorganic or organic material as filler, and a plurality of micro-reservoirs containing rasagiline. The substrate further comprises one or more substances for enhancing the transdermal absorption of rasagiline, in which the above organic polymer material in the substrate is used for the reservoir of rasagiline and as adhesive.
Owner:CHONGQING PHARMA RES INST +1
Closed loop nerve stimulation system
The invention belongs to the technical field of implantable medical instruments, and provides a closed loop deep brain stimulation system which can collect physiological signals of patients, adjust pulse stimulation parameters in real time and display data, store the data, design an optimization algorithm and update embedded programs in real time through an upper computer, and particularly relates to a closed loop nerve stimulation system. According to the closed loop nerve stimulation system, two closed loop work modes are provided; in one work mode, an implantable nerve stimulator carries out embedded algorithm data processing to form closed loop control; in the other work mode, the implantable nerve stimulator uploads the collected data to the upper computer through a wireless communication module, and then the upper computer carries out algorithm processing and then controls the stimulation parameters through the wireless communication module to form a closed loop. The closed loop nerve stimulation system can be used for closed loop electrical stimulation treatment of nervous system diseases or clinical research or animal research of a closed loop stimulation method and can provide a good platform for the research of the closed loop stimulation method.
Owner:TSINGHUA UNIV +1
MiR-124 gene knockout murine animal models as well as construction method and application thereof
ActiveCN106172238AShort modeling timeSimple methodNucleic acid vectorVector-based foreign material introductionAmyloid beta proteinsKnockout mouse
The invention discloses miR-124 gene knockout murine animal models. The murine animal models refer to mice with miR-124-1, miR-124-2 and miR-124-3 genes knocked out. With the adoption of a Crispr-cas9 gene knockout technology, microRNA (micro ribonucleic acid) miR-124 genes with the highest expression quantity in the brains of the mice are knocked out. The obtained mice show obvious nervous system disease states such as reduction of locomotor activity, deterioration of learning and memorizing abilities, increase of soluble amyloid beta protein and the like. Therefore, the simple, reliable and economical animal models can be provided for research of nervous system disease pathology and screening of drugs for treating nervous system diseases.
Owner:CENT SOUTH UNIV
Antibodies against Nogo receptor
InactiveUS20050214288A1Promote neuronalPromote axonal regenerationBiological material analysisImmunoglobulins against cell receptors/antigens/surface-determinantsRisk strokeNervous system disease
The present invention relates to antibodies and related molecules that specifically bind to the Nogo receptor (NogoR). Such antibodies have uses, for example, in the treatment of spinal cord injury, brain trauma, paralysis, degenerative nervous system diseases, and stroke. The invention also relates to nucleic acid molecules encoding anti-NogoR antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same.
Owner:HUMAN GENOME SCI INC
Method of nociceptor differentiation of human embryonic stem cells and uses thereof
ActiveUS20130183674A1Nervous disorderMicrobiological testing/measurementNervous systemLineage specific
The present invention relates to the field of stem cell biology, in particular the linage specific differentiation of pluripotent or multipotent stem cells, which can include, but is not limited to, human embryonic stem cells (hESC), human induced pluripotent stem cells (hiPSC), somatic stem cells, cancer stem cells, or any other cell capable of lineage specific differentiation. Specifically described are methods to direct the lineage specific differentiation of hESC and / or hiPSC to nociceptors (i.e. nociceptor cells) using novel culture conditions. The nociceptors made using the methods of the present invention are further contemplated for various uses including, but limited to, use in in vitro drug discovery assays, pain research, and as a therapeutic to reverse disease of, or damage to, the peripheral nervous system (PNS). Further, compositions and methods are provided for producing melanocytes from human pluripotent stem cells for use in disease modeling.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT
Viscous compositions containing carbon dioxide
InactiveUS6689339B1Effective treatmentTreating and preventing and ameliorating itchingOrganic active ingredientsAntimycoticsSide effectMusculoskeletal disease
A carbon dioxide-containing viscous composition wherein carbon dioxide bubbles are retained in an aqueous viscous composition. Use of the composition makes it possible to treat or ameliorate itching accompanying mucocutaneous diseases or mucocutaneous disorders, mucocutaneous injury, dental diseases, skin ulcer, cryesthesia and numbness caused by peripheral circulatory disorders, musculoskeletal diseases, nervous system diseases, keratosis, constipation, unwanted hair re-growing after depilation, cosmetic troubles in the skin or hair, partial obesity, etc. while exerting little side effects.
Owner:MEDION RES LAB
Benzoxazinone derivative
ActiveUS20100210636A1Excellent LCE inhibitory effectAntibacterial agentsOrganic active ingredientsReproductive system diseaseBenzoxazinones
[PROBLEMS]To provide a compound useful as an agent for the treatment of circulatory diseases, nervous system diseases, metabolic diseases, reproductive system diseases, and digestive tract diseases.[MEANS FOR SOLVING PROBLEMS]The compound, which is for use as an active ingredient, is represented by the formula (I):[wherein R1 represents optionally halogenated C1-6 alkyl, etc.; R2 represents, e.g., a group represented by the formula (II-1) or (II-4)(wherein W represents C1-6 alkylene, etc. and R represents C1-6 alkyl, etc.); R3 represents hydrogen, C1-6 alkyl, etc.; X represents —O—, —NH—, etc.; and Y1, Y2, Y3, and Y4 each independently represents —CH—, —N—, etc.].
Owner:MSD KK
Compositions for treating CNS disorders
An aminomethylpyridyloxymethyl / benzisoxazole substituted azabicyclic compound, a pharmaceutical composition comprising same, and a method of treating one or more CNS or other disorders, including concurrent treatment of disorders such as schizophrenia and depression.
Owner:PFIZER INC
Pharmacogenetic methods for use in the treatment of nervous system diseases
InactiveUS7001736B1Quick cureData can be usedData processing applicationsMicrobiological testing/measurementPharmacogeneticsClinical trial
The present invention provides a method for the determining the appropriate therapy and / or prognosis for a patient diagnosed with a non-Alzheimer's disease (AD) neurological disease based upon the patient's apoE allele load. The invention also provides a method for the identification of human subjects with a non-AD neurological disease that are likely to respond in clinical trials that test pharmaceuticals useful in the treatment of neurological diseases.
Owner:NOVARTIS INT PHARM LTD
Triage method and system for nervous system disease
InactiveCN108305690AGood effectMedical data miningSpecial data processing applicationsTriageDiagnostic data
The invention provides a triage method and system for a nervous system disease. The method provided by the invention comprises the steps: 1, carrying out the preprocessing of text data in a hospital electronic medical record, and extracting the symptoms and diagnostic data; 2, selecting the nervous system disease data for classification through a Bayes algorithm, and constructing a dedicated corpus; 3, constructing a training model based on a genetic algorithm, and carrying out the instructed learning of a training corpus; 4, modeling the classification after training, and constructing a triage knowledge graph of the nervous system disease.
Owner:王博冉
Biofeedback photoelectric therapeutic device
ActiveCN102019040ASelectivePurposefulMedical applicatorsLight therapyTreatment resultsCollection system
The invention relates to a biofeedback photoelectric therapeutic device comprising an information collection system, a control system and a biofeedback therapeutic system, wherein the information collection system is used for collecting physiologic information of a human cranial part in real time and transferring the physiologic information to the control system for analysis treatment; and the control system is used for controlling the biofeedback therapeutic system according to an analysis treatment result of the physiologic information to carry out the photoelectric stimulation therapy of corresponding nervous system diseases. The biofeedback photoelectric therapeutic device is used for measuring biological, chemical or physical signals of related tissues, particularly focal tissues through the information collection system, and the biofeedback therapeutic system is used for adopting corresponding therapeutic measures according to detected signal data. The invention has specificity, selectivity, stronger purposive property and safer and effective therapy.
Owner:SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI
Method for constructing KARS-gene-mutated mouse models and application of KARS-gene-mutated mouse models
ActiveCN106929533ANucleic acid vectorVector-based foreign material introductionSite-directed mutagenesisNervous system disease
The invention provides a method for constructing KARS-gene-mutated mouse models and application of the KARS-gene-mutated mouse models. The method for constructing the KARS-gene-mutated mouse models comprises the following steps: (1) carrying out target point construction: looking for a gene corresponding to nervous system diseases, and carrying out target point design; (2) designing Guide-RNA / Cas9mRNA, preparing plasmid, carrying out transcription, and then, injecting a transcription product into cytoplasm of a fertilized egg in a microinjection manner; (3) carrying out Founder mouse identification; (4) carrying out F1 mouse identification. According to the method for constructing the mouse models with the nervous system diseases and the application of the mouse models, provided by the invention, site-directed mutagenesis aiming at a KARS gene is carried out, so that a disease research on the model mice can be carried out under the condition of being closer to the occurrence and development of actual diseases, and a research result has a higher reference value.
Owner:XIN HUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Application of eucommia ulmoides extracts
InactiveCN101559092ASignificant sedative effectGood effectNervous disorderPlant ingredientsConvulsionSide effect
The invention discloses application of eucommia ulmoides extracts in the preparation of compositions for tranquilizing and inducing sleep and application of the eucommia ulmoides extracts in the preparation of compositions for treating insomnia, anxiety neurosis or convulsion. The eucommia ulmoides extracts are continuously extracted from eucommia bark, eucommia leaves, eucommia male flowers and\or eucommia whole plants by petroleum ether, ethyl acetate, normal butanol, ethanol and water. The eucommia ulmoides extracts are obtained by extracting from eucommia plants. And results of researcheson the application of the eucommia ulmoides extracts in the field of tranquilization and sleep induction show that the eucommia ulmoides extracts have remarkable effects of tranquilizing and inducingsleep and resisting convulsion, wherein the ethyl acetate extract of eucommia and the normal butanol extract of the eucommia have more obvious effects. The eucommia ulmoides extracts are natural active materials for researching and developing novel health-care foods and new drugs for tranquilizing and inducing sleep, and can be applied to the treatment of nervous system diseases such as insomnia,anxiety neurosis and convulsion without side effects and psychic dependence.
Owner:HENAN UNIV OF SCI & TECH
Methods for treating nervous system inquiry and disease
ActiveUS20080286267A1Promoting neuroprotectionBiocideNervous disorderProgenitorNervous system disease
The invention is directed to methods for treating nervous system injury and disease, in particular traumatic brain injury and degenerative nervous system disease. Such methods utilize novel compositions, including but not limited to trophic factor-secreting extraembryonic cells (herein referred to as TSE cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), each alone or in combination with each other and / or other agents.
Owner:STEMNION
Medical application of protopanaxatriol and protopanaxadiol in nervous system diseases
The invention relates to medical application of protopanaxa-triol (PPT), protopanaxadiol (PPD) and mixtures of the PPT and the PPD in any proportion in nervous system diseases, which are preferably used for treating and / or preventing epilepsy, cerebral ischemic diseases, memory disorder and parkinsonism syndrome.
Owner:王泽君
Cascade brain-targeting drug delivery system as well as preparation method and application thereof
InactiveCN102552105AAchieve precise targetingEnhance the imagePowder deliveryNervous disorderTreatment effectBrain tumor
The invention belongs to the field of pharmaceuticals and relates to a cascade brain-targeting drug delivery system and the application thereof. The cascade brain-targeting drug delivery system comprises a first-stage target functional molecule, a second-stage target functional molecule and a drug carrier. The cascade target drug delivery system can identify the blood-brain barrier through the first-stage target functional molecule and identify a brain lesion through the second-stage target functional molecule, so as to achieve the accurate targeting purpose, and can also accurately transfer imaging molecules or drugs to the brain lesion, so as to achieve good imaging and therapeutic effects. The cascade brain-targeting drug delivery system can be applied to prepare formulations for treatment or diagnosis of brain diseases (such as brain tumors) and nervous system diseases.
Owner:FUDAN UNIV
7-azaindirubin and 7-azaisoindigo derivative, its production and pharmaceutical use
ActiveCN101074229AImprove permeabilityImprove physical and chemical propertiesOrganic active ingredientsNervous disorderViral skin diseasesErythema induratum
A method for designing and synthesizing 7-azaindirubin and 7-azaisoindigo derivative and its medicinal use are disclosed. It changes indirubin and isoindigo nuclear-parent molecule atomic composition to form into compound. It also changes original molecule electric property. The process is carried out by coupling at different position by 7-azaindole and indole bi-molecule, inhibiting CDKs and CDKIs growth and breed and inducing CDKIs biological function. It can be used to treat malignant tumor, HIV and nervous system diseases.
Owner:JC (WUXI) CO INC
Wearable pupil light reflex measurement equipment
InactiveCN104545787AImprove portabilityIncrease flexibilityEye diagnosticsSoftware systemNeurosurgery
Owner:许昌红 +3
Dispersion tablet medicine containing oryzanol and its preparation method
InactiveCN1839850AImprove complianceMeet medication needsOrganic active ingredientsNervous disorderDiseaseAdjuvant
The invention relates to a dispersible tablet containing oryzanol for treating neurological system diseases and its preparing process, wherein the tablet comprises (by weight parts): oryzanol 5-200, filling agent 20-200, crumbling agent 15-40, bonding agent 1-70, flowing adjuvant or lubricating agent 0-5.
Owner:马志梅
Preparation method of brain tissue rapid freezing section
ActiveCN103674677ATo achieve the effect of quick freezingReduce formationPreparing sample for investigationAntigenPerfusion
The invention discloses a preparation method of a brain tissue rapid freezing section. According to the method, acetone is used as a freezing embedding medium and a liquid nitrogen intermediate medium, so that brain tissue can be rapidly frozen , and formation of ice crystals on the brain tissue can be effectively reduced; besides, factors affecting manufacturing quality, such as temperatures during material drawing and sectioning, fixing and soring conditions after sectioning and the like, of the freezing section are optimized, and the quality of the finally prepared section is further guaranteed. According to the brain tissue rapid freezing section obtained with the method, the freezing section which has stability and can well protect antigens and the enzyme activity is provided for further immunofluorescence, immunohistochemistry and in situ hybridization tests on the brain tissue, and a pathological section meeting requirements is provided for future clinical diagnosis related to nervous system diseases and scientific researches. Particularly, molecular and biochemical index detection can be further performed on other tissue of a mouse which is not subjected to perfusion treatment in the scientific research.
Owner:HARBIN MEDICAL UNIVERSITY
Method and apparatus for detection of nervous system disorders
ActiveUS7761146B2ElectroencephalographyPhysical therapies and activitiesNeurological problemsPhysical therapy
Owner:MEDTRONIC INC
Regulation of neurotrophins
Disclosed are methods for regulating neurotrophin levels within a human body. The invention utilizes an implantable signal generator to deliver stimulation to neural tissue elements. Alternatively, an implantable pump may be utilized to delivery one or more drugs. The implanted device delivers treatment therapy to the neural tissue to thereby alter the level of neurotrophic factors such as BDNF expressed by the influenced neural tissue. A sensor may be used to detect various symptoms of a nervous system disorder. A microprocessor algorithm may then analyze the output from the sensor to regulate the treatment therapy delivered to the body. The invention describes a novel method to regulate the intrinsic levels of neurotrophins and may be used to treat patients with neurological and cognitive disorders.
Owner:FUNCTIONAL NEUROMODULATION
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com